8 May 2020 in The AAPS Journal
Quality by design (QbD) is an efficient but challenging approach for the development of biosimilar due to the complex relationship among process, quality, and efficacy. Here, the analytical similarity of adalimumab biosimilar HLX03 to Humira® was successfully established following a QbD quality study. Quality target product profile (QTPP) of HLX03 was first generated according to the public available information and initial characterization of 3 batches of Humira®. The critical quality attributes (CQAs) were then identified through risk assessment according to impact of each quality attribute on efficacy and safety. The anticipated range for each CQA was derived from similarity acceptance range and/or the corresponding regulatory guidelines. Finally, a panel of advanced and orthogonal physicochemical and functional tests and comparison of 6 batches of HLX03 and 10 batches of the reference standard demonstrated high similarity of HLX03 to Humira®, except for slightly lower percentage of high mannosylated glycans (%HM) in HLX03 which had no effect on FcγRIII binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity in human peripheral blood mononuclear cell (PBMC). All above demonstrated the feasibility and efficiency of QbD-based similarity assessment of a biosimilar monoclonal antibody (mAb).
1 December 2019 in VideoGIE
15 April 2011 in Cancer Research
BAY 87–2243 is a novel small molecule inhibitor of hypoxia inducible factor-1α (HIF-1α) activity. Preclinical studies with BAY 87–2243 in a number of murine tumor models showed moderate to high tumor growth inhibition. The present study describes a non-invasive positron emission tomographic (PET) imaging method that monitors early therapeutic efficacy of this drug. To identify optimal tracer(s) for monitoring BAY 87–2243 anti-tumor activity, female nude mice were implanted on both scapulae with either 3.5×106 human non-small cell lung cancer (H460) or 2×106 human prostate cancer cells (PC3). Both are growth-inhibited by BAY 87–2243. Xenografts were grown to 200 mm3 over 10 days. Four PET tracers were assessed for uptake into tumor xenografts: 18F-FDG, 18F-FPP(RGD)2, 18F-FLT and 18F-FAZA. Tracers were injected via the tail vein. After pre-scan, BAY 87–2243 was orally administered, daily at 9mg/kg to 7 days. Tracer uptake was examined 1 and 3 day(s) after initial administration. Each treatment group for each PET tracer tested consisted of 6 tumors in 3 animals. At each imaging time point, RNA from BAY 87–2243-treated and vehicle-treated H460 tumor xenografts (3 additional animals each) was isolated. HIF target genes were quantified by Real-Time polymerase chain (RT-PCR) reaction. For both 18F-FDG and 18F-FPP(RGD)2, uptake was not significantly altered. However, 18F-FAZA tumor uptake (%ID mean/g) declined by 55–70% (1.21 ± 0.10 %ID/g to 0.35 ± 0.1 %ID/g, n=6, vehicle vs. treatment) in both H460 (p<0.001) and PC3 (p<0.05) models at both 1 and 3 days after drug administration. The decline occurred before any significant difference in tumor volume between drug- and vehicle-treated animals was observed, thus suggesting that decline in 18F-FAZA uptake reflected early changes in tumor biochemistry. A similar observation was noted for 18F-FLT in the H460 model, although the decline was less pronounced (30%; p<0.05 for all time-points). Analysis of HIF target gene expression by RT-PCR revealed that BAY 87–2243 reduced expression of the hypoxia regulated genes CA IX and ANGPTL4 by 99 % and 93 % respectively (p<0.001 for both) which corresponds with reduced 18F-FAZA uptake upon drug treatment. Reduced 18F-FLT uptake was not accompanied by reduced expression of TK1. Expression level of genes associated with glucose metabolism was heterogeneous and did not fully match with unchanged 18F-FDG uptake: GLUT-1 expression was unchanged while HK-2 decreased by 75 % (p<0.01). We detected low ITGB3 expression in untreated xenografts but were unable to detect transcripts after BAY 87–2243 treatment. This findings may explain the lack of change in 18F-FPP(RGD)2 uptake. In conclusion, our pilot studies suggest the suitability of 18F-FAZA-PET to monitor the efficacy of anti-cancer agents targeting the HIF pathway (e.g. BAY 87–2243) as an early PD marker prior to changes in tumor volume Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-147. doi:10.1158/1538-7445.AM2011-LB-147